Novel oral glucose lowering drugs cut risks in T2DM

February 8, 2017

(HealthDay)—For patients with type 2 diabetes, novel oral glucose lowering drugs (GLDs) are associated with reduced risks of all-cause mortality, cardiovascular disease (CVD), and hypoglycemia, compared with insulin use, according to a study published online Jan. 24 in Diabetes, Obesity and Metabolism.

Thomas Nyström, M.D., from Karolinska Institutet in Stockholm, and colleagues compared use of novel oral GLDs (either dipeptidyl-peptidase-4 inhibitors [DPP-4i] or sodium glucose cotransporter-2 inhibitors) with in a propensity score matched analysis involving 21,758 patients matched in a 1:1 ratio.

The researchers observed reductions in the risk of all-cause , CVD, and hypoglycemia in the novel GLD group versus the group (hazard ratios [HRs], 0.56 [95 percent confidence interval (CI), 0.49 to 0.64], 0.85 [95 percent CI, 0.73 to 0.99], and 0.26 [95 percent CI, 0.12 to 0.57], respectively). Dapagliflozin correlated with lower risks of all-cause mortality and CVD (HRs, 0.44 [95 percent CI, 0.28 to 0.70] and 0.51 [95 percent CI, 0.30 to 0.86], respectively), while DPP-4i correlated with reduced risk of all-cause mortality (HR, 0.59 [95 percent CI, 0.51 to 0.67]) but not CVD (HR, 0.87 [95 percent CI, 0.75 to 1.01]).

"Dapagliflozin was associated with lower risk of both all-cause mortality and CVD, whereas DPP-4i was only associated with lower risk of all-cause mortality," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Diabetes requiring insulin tied to increased stroke risk in A-fib

More information: Full Text (subscription or payment may be required)

Related Stories

Diabetes requiring insulin tied to increased stroke risk in A-fib

January 26, 2017
(HealthDay)—For patients with atrial fibrillation (AF), diabetes requiring insulin, but not diabetes without insulin treatment, is associated with an increased risk of stroke/systemic embolism, according to a study published ...

Varying safety of add-on second-line T2DM treatments

June 17, 2016
(HealthDay)—For patients with type 2 diabetes who are taking metformin, the risk of cardiovascular events and mortality varies with the addition of different second-line therapies, according to a study published online ...

Lowest glucose variability for insulin + GLP-1 RA in T2DM

December 20, 2016
(HealthDay)—For patients with type 2 diabetes, the lowest glucose variability (GV) and hypoglycemia is seen for patients using basal insulin + glucagon-like peptide 1 receptor agonist (GLP-1 RA) (BGLP), according to a study ...

Low blood glucose levels in hospitalized patients linked to increased mortality risk

November 17, 2016
In hospitalized patients, low blood sugar—also known as hypoglycemia—is associated with increased short- and long-term mortality risk, according to a new study published in the Endocrine Society's Journal of Clinical ...

Beta-blockers linked to reduced mortality in HFrEF, A-fib

January 12, 2017
(HealthDay)—β-blockers are associated with significantly reduced mortality, but not hospitalizations, in patients with heart failure and reduced ejection fraction (HFrEF) and atrial fibrillation (AF), according to a study ...

Insulin glargine 300 U/mL beats glargine 100 U/mL in T1DM

January 31, 2017
(HealthDay)—For patients with type 1 diabetes, receipt of insulin glargine 300 U/mL (Gla-300) is associated with better glucose control than glargine 100 U/mL (Gla-100), regardless of injection time, according to a study ...

Recommended for you

High blood pressure linked to common heart valve disorder

October 17, 2017
For the first time, a strong link has been established between high blood pressure and the most common heart valve disorder in high-income countries, by new research from The George Institute for Global Health at the University ...

Saving hearts after heart attacks: Overexpression of a gene enhances repair of dead muscle

October 17, 2017
University of Alabama at Birmingham biomedical engineers report a significant advance in efforts to repair a damaged heart after a heart attack, using grafted heart-muscle cells to create a repair patch. The key was overexpressing ...

Diabetes pill might replace injection to control blood sugar

October 17, 2017
(HealthDay)— An injectable class of diabetes medication—called glucagon-like peptide-1 or GLP-1—might one day be available in pill form, research suggests.

Skimping on sleep may contribute to gestational diabetes

October 17, 2017
The amount of time spent sleeping in the United States has dropped significantly in the past twenty years with almost a quarter of women and 16 percent of men experiencing insufficient sleep. Now, a new study has found that ...

Artificial pancreas performs well in clinical trial

October 16, 2017
During more than 60,000 hours of combined use of a novel artificial pancreas system, participants in a 12-week, multi-site clinical trial showed significant improvements in two key measures of well-being in people living ...

Blood cancer gene could be key to preventing heart failure

October 16, 2017
A new study, published today in Circulation, shows that the gene Runx1 increases in damaged heart muscle after a heart attack. An international collaboration led by researchers from the University of Glasgow, found that mice ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.